Abiopharma

Dominari Holdings Files $2 Billion Shelf to Support Strategic Expansion

New Form 8-K - Imunon, Inc. Filed: 2025-08-28 AccNo: 0001493152-25-012417 Size: 235 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits

SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

LifeMD to Participate in Three Investor Conferences During September

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

New Form S-3 - Dominari Holdings Inc. Filed: 2025-08-28 AccNo: 0001213900-25-081384 Size: 755 KB

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Merus to Present at the 2025 Wells Fargo Healthcare Conference

Collegium to Participate in Upcoming Investor Conferences

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences